Mode
Text Size
Log in / Sign up

Chest wall radiotherapy results in worse chest wall symptoms but no other quality of life impactsTrial shows chest wall radiotherapy affects symptoms in breast cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that chest wall radiotherapy causes worse local symptoms but no significant impact on other QOL domains like fatigue.

This Phase 3 randomized controlled trial investigated the impact of chest wall radiotherapy on quality of life (QOL) in a specific population of women with intermediate-risk breast cancer. The study enrolled patients who had been diagnosed with intermediate-risk breast cancer (pT1-2N1, pT3N0, or pT2N0 with histological grade 3, or lymphovascular invasion, or both) and underwent mastectomy and axillary surgery. The trial was an international multi-center study; however, it is noted that the QOL substudy specifically included patients from the UK.

The study randomized 1679 patients into two groups: 845 received chest wall radiotherapy (40-50 Gy in 15-25 fractions) and 834 received no radiotherapy. The QOL substudy, which focused on patient-reported outcomes, included a total of 989 patients. Follow-up assessments were conducted at intervals of 1, 2, 5, and 10 years to monitor long-term outcomes.

The primary outcome of the main trial was overall survival; however, this specific QOL substudy report did not provide data for that primary endpoint. The secondary outcomes included Global QOL, fatigue, physical function, chest wall symptoms, shoulder and arm symptoms, body image, anxiety, and depression. Regarding chest wall symptoms, patients in the radiotherapy group experienced significantly worse symptoms compared to those who did not receive radiation (1.99; 95% CI 0.36-3.62; p=0.017). These symptoms showed improvement between years 1, 2, and 5.

Other secondary outcomes, including arm symptoms, body image, fatigue, pain, overall QOL, physical functioning, anxiety, and depression, showed no statistically significant differences between the radiotherapy and no-radiotherapy groups. A specific analysis regarding chemotherapy revealed that it was associated with less improvement over time (2.97; 95% CI 0.24-5.71; p=0.033), though there was no interaction observed between chemotherapy and chest wall radiotherapy. Furthermore, a subgroup analysis of surgical techniques showed that patients who underwent sentinel lymph node biopsy followed by axillary lymph node clearance combined with chest wall radiotherapy had worse chest wall symptoms than those undergoing a single axillary operation (-5.29; 95% CI -8.53 to -2.05; p=0.0015).

Safety and tolerability data, including specific adverse event rates or discontinuation rates, were not reported in this substudy. The trial's findings suggest that while chest wall radiotherapy is associated with localized toxicity (worse symptoms), it does not appear to negatively impact broader QOL metrics like body image or physical function at the 5-year mark.

The study design provides high-level evidence as a Phase 3 randomized controlled trial. However, several limitations must be considered. The QOL substudy only included patients from the UK, which may limit the generalizability of these specific QOL findings to international populations. Additionally, while the association between chemotherapy and less improvement over time was noted, it is not a direct interaction with the radiotherapy itself.

Clinically, these results suggest that clinicians can inform patients that chest wall radiotherapy may lead to increased local symptoms (chest wall toxicity), but evidence does not currently support a corresponding decline in other QOL domains such as anxiety or body image. The specific risk of worse outcomes following complex surgery (sentinel lymph node biopsy followed by axillary clearance) combined with radiation should be considered when counseling patients on surgical and treatment pathways. Questions remain regarding the long-term impact of these symptoms beyond the 5-year mark and how different types of chemotherapy might specifically influence the trajectory of symptom improvement. Further research is needed to determine if specific interventions can mitigate the localized chest wall symptoms caused by radiation without affecting other QOL factors.

How this fits prior evidence

How this fits prior evidence: This study addresses a gap in understanding the specific quality of life impacts of local treatments for breast cancer. While previous findings established that certain medications like Trop-2 directed ADCs improve progression free survival, this trial focuses on the localized impact of radiotherapy. It does not relate to the reported findings regarding dietary antioxidant capacity, radiation dermatitis thresholds (Mepitel film), endocrine disruptors, or nutrition education programs.

When a woman is diagnosed with intermediate-risk breast cancer, doctors must decide on the best way to treat the area around the chest wall. One common method is radiotherapy, which uses radiation to target any remaining cancer cells. While this treatment aims to keep the cancer from returning, it can sometimes cause physical discomfort or local symptoms in the chest area. For many patients, understanding how these treatments affect their daily lives and comfort is a vital part of making an informed choice.

To better understand this, researchers conducted a large-scale study involving over 1,600 women who had undergone surgery for breast cancer. The participants were split into two groups: one group received chest wall radiotherapy, and the other did not. Researchers followed these women for up to 10 years to see how they felt physically and emotionally, specifically looking at things like fatigue, body image, arm movement, and pain.

The results showed a specific trade-off regarding local symptoms. Women who received radiation reported worse chest wall symptoms compared to those who did not. However, these symptoms actually showed signs of improvement between the first and fifth years after treatment. Interestingly, while the radiation caused more localized issues, it did not make a difference in other areas of life. Factors like fatigue, anxiety, depression, body image, and physical function were all similar between both groups. This means that for most aspects of daily life, the radiation did not cause additional problems.

There was also a specific finding regarding surgery types. Women who had a more complex surgical process involving multiple steps before receiving radiation reported even worse chest wall symptoms than those who had a single operation. Additionally, patients who underwent chemotherapy saw less improvement in their symptoms over time compared to those who did not receive it, though the radiation itself did not change that specific trend.

It is important to keep these findings in perspective. This specific data on quality of life only included patients from the UK, so it may not represent every patient globally. Furthermore, while the study shows a link between radiation and local symptoms, it does not mean everyone will experience discomfort. Doctors use this information to help patients weigh the benefits of radiation against potential side effects. For now, these results provide a clearer picture of what to expect regarding chest wall comfort following treatment.

What this means for you:
Radiotherapy may cause more local chest wall symptoms but does not impact other quality of life factors like fatigue.

Study Details

Study typeRct
Sample sizen = 845
EvidenceLevel 2
Follow-up120.0 mo
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: The SUPREMO trial reported adjuvant chest wall radiotherapy had no effect on 10-year overall survival (primary endpoint) in patients with intermediate-risk breast cancer after mastectomy. The quality of life (QOL) substudy of SUPREMO (UK patients only) examines the effects of chest wall radiotherapy in patients with intermediate-risk breast cancer 1 year, 2 years, 5 years, and 10 years after treatment. Here, we report 5-year QOL results (a secondary endpoint), including prespecified subgroup analyses. METHODS: SUPREMO is an international, parallel-group, randomised, controlled, phase 3 trial. Women aged 18 years or older with intermediate-risk breast cancer (defined as pT1-2N1 or pT3N0 or pT2N0 with histological grade 3, or lymphovascular invasion, or both) who had undergone mastectomy (and axillary surgery) were randomly assigned (1:1) to receive chest wall radiotherapy (40-50 Gy in 15-25 fractions) or no radiotherapy. Randomisation was in permuted blocks with varying block length, stratified by centre, without masking of patients or investigators. All UK patients were invited to the QOL substudy. Consenting patients completed validated questionnaires (European Organisation for Research and Treatment of Cancer Quality of Life Core 30-item questionnaire; European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Breast Cancer Module, 23 items; Body Image Scale; and Hospital Anxiety and Depression Scale) before randomisation and at 1 year, 2 years, 5 years, and 10 years. Here, we report the prespecified primary QOL outcomes of global QOL, fatigue, physical function, chest wall symptoms, shoulder and arm symptoms, body image, anxiety, and depression in the intention to treat population, using repeated measures mixed-effects models. This trial is registered with the ISRCTN registry, ISRCTN61145589 and is now completed. FINDINGS: Between Aug 4, 2006, and April 29, 2013, SUPREMO recruited 1691 patients internationally, of whom 1679 were randomly assigned to receive chest wall radiotherapy (n=845) or not (n=834). Of 1233 patients from UK centres (619 in the chest wall radiotherapy group and 614 in the no chest wall radiotherapy group), 989 (80%) consented to the QOL substudy: 947 (96%) of 989 returned baseline questionnaires and 620 (75%) of 832 patients returned the expected year-5 questionnaires. Chest wall symptoms were worse with chest wall radiotherapy (effect estimate 1·99 [95% CI 0·36-3·62]; p=0·017) with an improvement between years 1, 2, and 5. Chemotherapy was associated with less improvement over time (effect estimate 2·97 [95% CI 0·24-5·71]; p=0·033) but without interaction with chest wall radiotherapy. No statistically significant differences were observed in other QOL domains (arm symptoms, body image, fatigue, pain, overall QOL, physical functioning, or anxiety and depression). In the subgroup analyses, patients who had a sentinel lymph node biopsy followed up by an axillary lymph node clearance with chest wall radiotherapy had worse chest wall symptoms than those having a single axillary operation (difference chest wall radiotherapy vs no chest wall radiotherapy -5·29 [95%CI -8·53 to -2·05]; p=0·0015). INTERPRETATION: The 5-year QOL findings showed worse chest wall toxicity and no effect on other QOL domains. The subgroup analyses suggested a potential negative effect of chemotherapy and axillary clearance after sentinel node biopsy. FUNDING: UK Medical Research Council, National Institute for Health and Care Research, European Organisation for Research and Treatment of Cancer, Edinburgh Trustees of Breast Cancer Institute in Edinburgh and the Edinburgh Cancer Centre NHS Endowment funds, The Dutch Cancer Society, Trustees of the Hong Kong and Shanghai Banking Corporation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.